Adams initiated by Merrill Lynch at neutral

Adams Respiratory Therapeutics Inc. was initiated by Merrill Lynch analyst Gregory Gilbert at a neutral. The firm believes that the Mucinex story is compelling, but investors are already paying for some of the potential upside that Mucinex DM and D could generate if the FDA removes competitive products from the market. Adams shares Wednesday were down $0.67, or 2.06%, at $31.91 on volume of 234,147 shares versus the three-month running average of 490,997 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.